MENU
+Compare
EMBC
Stock ticker: NASDAQ
AS OF
Jan 14 closing price
Price
$12.75
Change
+$0.09 (+0.71%)
Capitalization
754.95M

EMBC stock forecast, quote, news & analysis

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes... Show more

EMBC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EMBC showed earnings on November 25, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for EMBC with price predictions
Jan 13, 2026

EMBC's RSI Indicator ascending out of oversold territory

The RSI Oscillator for EMBC moved out of oversold territory on December 10, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In of the 26 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 06, 2026. You may want to consider a long position or call options on EMBC as a result. In of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EMBC just turned positive on December 16, 2025. Looking at past instances where EMBC's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .

EMBC moved above its 50-day moving average on January 08, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EMBC advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 114 cases where EMBC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMBC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EMBC broke above its upper Bollinger Band on January 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (11.802). P/E Ratio (7.870) is within average values for comparable stocks, (168.298). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.531). EMBC has a moderately high Dividend Yield (0.047) as compared to the industry average of (0.017). P/S Ratio (0.695) is also within normal values, averaging (113.639).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EMBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EMBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Dividends

EMBC paid dividends on December 18, 2025

Embecta Corp EMBC Stock Dividends
А dividend of $0.15 per share was paid with a record date of December 18, 2025, and an ex-dividend date of December 05, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 12.08B. The market cap for tickers in the group ranges from 246 to 193.82B. ISRG holds the highest valuation in this group at 193.82B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was -0%. ECIA experienced the highest price growth at 25%, while ZJYL experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 64
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 93
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
EMBC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
N/A
Address
300 Kimball Drive
Phone
+1 862 401-0000
Employees
2200
Web
https://www.embecta.com